EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The medical and functional burden of surviving childhood ependymoma: A population‐based study in Ontario, Canada

Hallie Coltin iD, Priscila Pequeno, Ning Liu, Derek S Tsang, Sumit Gupta iD, Michael D Taylor, Eric Bouffet iD, Vijay Ramaswamy iD, Paul C Nathan iD

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31275 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Hallie Coltin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Ependymoma, Cancer Survivors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Garron Family Cancer Centre Fellowship, Fondation Charles-Bruneau Fellowship, Garron Family Cancer Centre Pitblado Discovery Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Few studies have characterized the burden of late effects among childhood ependymoma survivors. To address this gap, we examined these sequelae using real‐world health services data in a population‐based ependymoma survivor cohort.

Methods

All individuals younger than 18 years diagnosed with an ependymoma in Ontario, Canada between 1987 and 2015 who had survived at least 5 years from their latest pediatric cancer event (index date) were matched 1:5 with population controls. Following linkage with provincial health services data, the cumulative incidences of multiple medical and functional outcomes between survivors and controls were compared.

Results

Among 96 survivors, 77.1% had been irradiated and 9.4% had received cisplatin. At 10 years post‐index, survivors were at significantly higher risk of all‐cause mortality (7.1%, 95% confidence interval [CI]: 1.0–13.3 vs. 0.3%, 95% CI: 0.0–1.0; p = .0002), non‐obstetric hospitalization (45.1%, 95% CI: 32.6–56.7 vs. 10.6%, 95% CI: 7.6–14.1; p < .0001), stroke (6.5%, 95% CI: 2.3–13.7 vs. 0%; p < .0001), severe hearing loss requiring an amplification device (7.5%, 95% CI: 2.7–15.7 vs. 0%; p < .0001), receiving homecare service (27.6%, 95% CI: 18.5–37.5 vs. 7.7%, 95% CI: 5.3–10.7; p < .0001), and submitting a disability support prescription claim (24.0%, 95% CI: 14.8–34.3 vs. 5.4%, 95% CI: 3.5–7.8; p < .0001) compared to controls.

Conclusions

Pediatric ependymoma survivors are highly vulnerable to severe late sequelae, including death, stroke, severe hearing loss, and disability. Urgent efforts are needed to improve risk‐stratification approaches that mitigate exposure to toxic therapies for children with lower risk disease. Interventions to prevent or decrease the risk of developing late sequelae are critical to optimizing survivor long‐term health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpendymomaCancer SurvivorsHumansMaleFemaleChildOntarioAdolescentChild, PreschoolInfantFollow-Up StudiesSurvival RateCase-Control StudiesPrognosis

Stichwörter der Autor:innen

chemotherapyependymomapediatricradiationsurvivorship

Autor:innen und Institutionen

  • Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada.
  • Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.
  • Programme in Developmental and Stem Cell Biology, Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, Ontario, Canada.
  • ICES, Toronto, Ontario, Canada.
  • Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
  • Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

ORCID-Profile: Hallie Coltin, Sumit Gupta, Eric Bouffet, Vijay Ramaswamy, Paul C Nathan

Förderung

  • Garron Family Cancer Centre Fellowship
  • Fondation Charles-Bruneau Fellowship
  • Garron Family Cancer Centre Pitblado Discovery Grant
  • Empowering Next-generation Researchers In perinatal and Child Health (ENRICH) New Investigator Award
  • Rally Foundation for Childhood Cancer Research Young Investigator Award
  • Brain Tumour Foundation of Canada Feature Grant
  • University of Montreal Faculty of Medicine Clinician-Scientist Award
  • Canadian Cancer Society Research Institute Emerging Scholars Award

Zitieren

APA

Coltin, H., Pequeno, P., Liu, N., Tsang, D. S., Gupta, S., Taylor, M. D., Bouffet, E., Ramaswamy, V., & Nathan, P. C. (2024). The medical and functional burden of surviving childhood ependymoma: A population‐based study in Ontario, Canada. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31275

Vancouver

Coltin H, Pequeno P, Liu N, Tsang DS, Gupta S, Taylor MD, et al. The medical and functional burden of surviving childhood ependymoma: A population‐based study in Ontario, Canada. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31275

BibTeX
@article{Coltin2024,
  author = {Coltin, Hallie and Pequeno, Priscila and Liu, Ning and Tsang, Derek S and Gupta, Sumit and Taylor, Michael D and Bouffet, Eric and Ramaswamy, Vijay and Nathan, Paul C},
  title = {The medical and functional burden of surviving childhood ependymoma: A population‐based study in Ontario, Canada},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31275}
}
Kostenlos starten →